You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
30 June 2026 - Grünenthal, a Germany-based pharmaceutical company, announced on Monday that the company has successfully concluded a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist.The company says that in the...
29 June 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ: NTRA) and Aveta Biomics Inc, a clinical-stage immuno-oncology company, on Monday announced a strategic partnership to support Aveta's global Phase 3 registrational t...
29 June 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq: UTHR) announced on Monday that it has received U.S. Food and Drug Administration premarket approval for the LungFX device, the first system approved for centralised ex vivo...
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of upadacitinib for adult...
29 June 2026 - Biotechnology company Evommune Inc (NYSE: EVMN) disclosed on Monday that its Phase 2b trial evaluating EVO756 in moderate-to-severe chronic spontaneous urticaria did not meet its primary endpoint.The randomised, double-blind, placebo-c...
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of upadacitinib for ...
29 June 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN), announced on Monday that together with Daiichi Sankyo Company Limited, it has received a positive recommendation from the European Medicines Agency's Com...